Common variations in BARD1 influence susceptibility to high-risk neuroblastoma
暂无分享,去创建一个
Nazneen Rahman | Sharon J. Diskin | John M. Maris | Struan F. A. Grant | Joseph T. Glessner | Hakon Hakonarson | Wendy B. London | Cynthia Winter | Cuiping Hou | Cecilia Kim | Shahab Asgharzadeh | Robert C. Seeger | Mario Capasso | J. Glessner | H. Hakonarson | Cecilia Kim | S. Grant | N. Rahman | K. Cole | J. Bradfield | E. Rappaport | M. Devoto | J. Maris | R. Scott | S. Diskin | E. Attiyeh | S. Asgharzadeh | M. Diamond | Y. Mossé | W. London | R. Seeger | M. Capasso | C. Hou | Hongzhe Li | C. Mcconville | J. Jagannathan | C. Winter | Marcella Devoto | Eric Rappaport | Jonathan P. Bradfield | Maria Garris | Maura Diamond | Kristina A. Cole | Edward F. Attiyeh | Yael P. Mosse | M. Laudenslager | K. Bosse | Hongzhe Li | Marci Laudenslager | Richard H. Scott | Kristopher Bosse | Jayanti Jagannathan | Carmel McConville | M. Garris | C. McConville | Jayanti Jagannathan
[1] Laurent Briollais,et al. SNP-SNP interactions in breast cancer susceptibility , 2006, BMC Cancer.
[2] Mark Daly,et al. Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..
[3] J. Gulcher,et al. The BARD1 Cys557Ser Variant and Breast Cancer Risk in Iceland , 2006, PLoS medicine.
[4] Anne M. Bowcock,et al. Identification of a RING protein that can interact in vivo with the BRCA1 gene product , 1996, Nature Genetics.
[5] D. Reich,et al. Population Structure and Eigenanalysis , 2006, PLoS genetics.
[6] Heli Nevanlinna,et al. BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition , 2006, European Journal of Human Genetics.
[7] F. Berthold,et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. , 2005, The Lancet. Oncology.
[8] B. Hero,et al. Neuroblastoma , 2007, The Lancet.
[9] F. Berthold,et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Manuel A. R. Ferreira,et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.
[11] G. Giles,et al. The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case–control and family analysis , 2009, Breast Cancer Research and Treatment.
[12] D. Reich,et al. Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.
[13] K K Matthay,et al. Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .
[14] Lester L. Peters,et al. Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.
[15] C. Jefford,et al. Is there more to BARD1 than BRCA1? , 2006, Nature Reviews Cancer.
[16] D. Stram,et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] John M. Maris,et al. Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.
[18] Nazneen Rahman,et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. , 2008, The New England journal of medicine.
[19] W. Willett,et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.